File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration

TitlePrecisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration
Authors
Keywordsabaloparatide
bone regeneration
hydrogel
methacrylated gelatin
parathyroid hormone
Issue Date2019
PublisherWiley - V C H Verlag GmbH & Co KGaA. The Journal's web site is located at http://www.wiley-vch.de/vch/journals/2127/index.html
Citation
Macromolecular Bioscience, 2019, v. 19 n. 6, p. article no. 1900020 How to Cite?
AbstractSide-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments. With the advance of tissue engineering, hydrogel injection therapy is introduced as an alternative treatment. Therapeutic drugs and growth factors can be carried by hydrogels and delivered to patients. Abaloparatide, as an analog of human recombinant parathyroid hormone protein (PTHrp) and an alternative to teriparatide, has been considered as a drug for treating postmenopausal osteoporosis since 2017. Since only limited cases of receiving abaloparatide with polymeric scaffolds have been reported, the effects of abaloparatide on pre-osteoblast MC3T3-E1 are investigated in this study. It is found that in vitro abaloparatide treatment can promote pre-osteoblast MC3T3-E1 cells’ viability, differentiation, and mineralization significantly. For the drug delivery system, 3D porous structure of the methacrylated gelatin (GelMA) hydrogel is found effective for prolonging the release of abaloparatide (more than 10 days). Therefore, injectable photo-crosslinked GelMA hydrogel is used in this study to prolong the release of abaloparatide and to promote healing of defected bones in rats. Overall, data collected in this study show no contradiction and imply that Abaloparatide-loaded GelMA hydrogel is effective in stimulating bone regeneration
Persistent Identifierhttp://hdl.handle.net/10722/272057
ISSN
2017 Impact Factor: 3.392
2015 SCImago Journal Rankings: 1.257

 

DC FieldValueLanguage
dc.contributor.authorNING, Z-
dc.contributor.authorTan, B-
dc.contributor.authorChen, B-
dc.contributor.authorLau, DSA-
dc.contributor.authorWong, TM-
dc.contributor.authorSUN, T-
dc.contributor.authorPeng, S-
dc.contributor.authorLi, Z-
dc.contributor.authorLu, WW-
dc.date.accessioned2019-07-20T10:34:49Z-
dc.date.available2019-07-20T10:34:49Z-
dc.date.issued2019-
dc.identifier.citationMacromolecular Bioscience, 2019, v. 19 n. 6, p. article no. 1900020-
dc.identifier.issn1616-5187-
dc.identifier.urihttp://hdl.handle.net/10722/272057-
dc.description.abstractSide-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments. With the advance of tissue engineering, hydrogel injection therapy is introduced as an alternative treatment. Therapeutic drugs and growth factors can be carried by hydrogels and delivered to patients. Abaloparatide, as an analog of human recombinant parathyroid hormone protein (PTHrp) and an alternative to teriparatide, has been considered as a drug for treating postmenopausal osteoporosis since 2017. Since only limited cases of receiving abaloparatide with polymeric scaffolds have been reported, the effects of abaloparatide on pre-osteoblast MC3T3-E1 are investigated in this study. It is found that in vitro abaloparatide treatment can promote pre-osteoblast MC3T3-E1 cells’ viability, differentiation, and mineralization significantly. For the drug delivery system, 3D porous structure of the methacrylated gelatin (GelMA) hydrogel is found effective for prolonging the release of abaloparatide (more than 10 days). Therefore, injectable photo-crosslinked GelMA hydrogel is used in this study to prolong the release of abaloparatide and to promote healing of defected bones in rats. Overall, data collected in this study show no contradiction and imply that Abaloparatide-loaded GelMA hydrogel is effective in stimulating bone regeneration-
dc.languageeng-
dc.publisherWiley - V C H Verlag GmbH & Co KGaA. The Journal's web site is located at http://www.wiley-vch.de/vch/journals/2127/index.html-
dc.relation.ispartofMacromolecular Bioscience-
dc.rightsThis is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectabaloparatide-
dc.subjectbone regeneration-
dc.subjecthydrogel-
dc.subjectmethacrylated gelatin-
dc.subjectparathyroid hormone-
dc.titlePrecisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration-
dc.typeArticle-
dc.identifier.emailLau, DSA: dsl115@hku.hk-
dc.identifier.emailWong, TM: wongtm@hku.hk-
dc.identifier.emailLu, WW: wwlu@hku.hk-
dc.identifier.authorityWong, TM=rp01689-
dc.identifier.authorityLu, WW=rp00411-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/mabi.201900020-
dc.identifier.pmid31066995-
dc.identifier.scopuseid_2-s2.0-85065525529-
dc.identifier.hkuros298571-
dc.identifier.volume19-
dc.identifier.issue6-
dc.identifier.spagearticle no. 1900020-
dc.identifier.epagearticle no. 1900020-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats